Obesity is a silent killer, and its impact on breast cancer is a growing concern. But could a diabetes treatment be the unexpected hero in this story? SABCS 2025 reveals intriguing findings!
At the recent San Antonio Breast Cancer Symposium, researchers delved into the use of glucagon-like peptide 1 (GLP-1) receptor agonists, typically used for weight management, and their potential role in breast cancer care. The study, presented by Ryals et al., analyzed a massive dataset of over 700,000 breast cancer patients' electronic health records from 2011 to 2025.
Who benefits from GLP-1 therapy?
The analysis revealed that 7.6% of patients were prescribed GLP-1, mainly for diabetes, weight loss, cardiovascular problems, or sleep apnea. Interestingly, certain groups showed a higher prevalence of GLP-1 use: those with a higher body mass index (BMI), non-Latinx Black individuals, telemedicine users, and rural residents. Conversely, older patients, those with advanced cancer stages, specific tumor types, Latinx and Asian patients, and those with limited English skills were less likely to receive GLP-1 therapy, especially if they were treated at community medical centers.
A surprising link to tumor activity:
Here's where it gets fascinating. Patients on GLP-1 therapy underwent ctDNA testing more frequently and had lower ctDNA positivity rates. This hints at a potential relationship between GLP-1 and reduced tumor activity in the bloodstream, suggesting these medications might have a role beyond weight control in oncology.
Unraveling the mysteries:
The study emphasizes the intricate interplay of clinical, sociodemographic, and social determinants of health (SDOH) in GLP-1 use. It also highlights disparities in access to this therapy. Researchers now call for further investigations to clarify if GLP-1 directly influences breast cancer outcomes and to ensure fair access to supportive treatments for all patients, regardless of their background.
This groundbreaking analysis opens doors to new possibilities, leaving us with a crucial question: Could GLP-1 be a hidden ally in the fight against breast cancer? The journey to uncover the full potential of this therapy has only just begun, and the answers may surprise us all.
